Innovent and Lilly present findings on lung cancer combination

21 September 2020

Chinese biopharma Innovent Biologics (HKG: 1801) and US drugmaker Eli Lilly (NYSE: LLY) have jointly announced that biomarker results from the ORIENT-11 study were released in a mini oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

ORIENT-11 is a randomized, double-blind, Phase III trial evaluating Tyvyt (sintilimab injection) or placebo in combination with Alimta (pemetrexed) and platinum chemotherapy as a first-line treatment for advanced or recurrent nonsquamous non-small cell lung cancer (nsqNSCLC) without sensitizing EGFR mutations or ALK rearrangements.

Biomarker data analysis revealed that the MHC-II antigen presentation pathway played a key role in the immunotherapy-chemotherapy combination. Higher gene expression of this pathway was significantly associated with longer progression-free survival and could potentially serve as a predictive biomarker to select patients who can benefit from this regimen.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK